FNY Investment Advisers LLC Acquires 338 Shares of Zoetis Inc. (NYSE:ZTS)

FNY Investment Advisers LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 22.5% in the first quarter, Holdings Channel.com reports. The fund owned 1,837 shares of the company’s stock after buying an additional 338 shares during the quarter. FNY Investment Advisers LLC’s holdings in Zoetis were worth $302,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. Norges Bank bought a new stake in Zoetis during the 4th quarter valued at $824,321,000. Wellington Management Group LLP raised its position in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Sarasin & Partners LLP bought a new stake in Zoetis during the 1st quarter valued at $339,111,000. GAMMA Investing LLC raised its position in Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company’s stock valued at $289,666,000 after purchasing an additional 1,747,423 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Zoetis during the 4th quarter valued at $196,651,000. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Piper Sandler lifted their price target on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $212.75.

Zoetis Stock Down 2.7%

Shares of ZTS stock opened at $164.27 on Monday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The stock’s fifty day moving average price is $158.67 and its 200 day moving average price is $163.83. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market cap of $73.13 billion, a price-to-earnings ratio of 30.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.38 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis’s payout ratio is presently 35.91%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.18% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.